OREANDA-NEWS. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) (“Amphastar” or the “Company”), announced today that, through its wholly owned UK subsidiary, Amphastar UK Limited, acquired a UK based corporation, International Medication Systems (UK) Limited, including its product trademarks, and other related product assets, as well as Marketing Authorizations for thirty-three products in the UK, Ireland, Australia, and New Zealand, representing eleven different injectable chemical entities, from UCB PHARMA GmbH for $7.7 million. The products are generic injectables containing the following active ingredients; Adrenaline, Amiodarone, Atropine, Calcium Chloride, Furosemide, Glucose, Lidocaine, Magnesium Sulphate, Morphine, Naloxone and Sodium Bicarbonate. Amphastar plans to transfer the products to its facilities in California.  The transfer will require UK MHRA and other related regulatory agency approval before the products can be re-launched.

Amphastar’s CEO, Dr. Jack Zhang, Ph.D. stated, “We are very happy to be able to expand our presence into the international market with this transaction and to reunite the UK IMS entity with the US IMS entity.”

Company Information

Amphastar is a specialty pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin active pharmaceutical ingredient products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.